Somatostatin and Octreotide on the treatment of acute Pancreatitis - basic and clinical studies for three decades

Current Pharmaceutical Design

Volumn 17, Issue 16, 2011, Pages 1594-1601

  Li, Jing ^a   Wang, Rui ^a   Tang, Chengwei ^a  

^a SICHUAN UNIVERSITY   (China)

Author keywords

Acute pancreatitis; APACHE II score; Chronic alcoholics; Nuclear factor kappa B; Obesity; Octreotide; Somatostatin; Sphincter of oddi

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1BETA; INTERLEUKIN 6; OCTREOTIDE; TOLL LIKE RECEPTOR 4; TUMOR NECROSIS FACTOR ALPHA;

ABSENCE OF SIDE EFFECTS; ACINAR CELL; ACUTE PANCREATITIS; ADULT RESPIRATORY DISTRESS SYNDROME; ALCOHOL CONSUMPTION; ALCOHOLISM; ANTIINFLAMMATORY ACTIVITY; CALCIUM SIGNALING; CELL DEATH; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; CRITICAL ILLNESS; CYTOKINE RELEASE; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG HALF LIFE; ENZYME RELEASE; GENE OVEREXPRESSION; HIGH RISK POPULATION; HISTOPATHOLOGY; HUMAN; IMMUNE RESPONSE; INTESTINE ISCHEMIA; INTESTINE PERFORATION; INTESTINE PERFUSION; MULTIPLE ORGAN FAILURE; NEUROENDOCRINOLOGY; NONHUMAN; OBESITY; ODDI SPHINCTER; PANCREAS SECRETION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; TRANSLATIONAL RESEARCH; TREATMENT DURATION; TREATMENT OUTCOME; WAIST CIRCUMFERENCE;

ACUTE DISEASE; HUMANS; OCTREOTIDE; PANCREATITIS; SOMATOSTATIN;

EID: 79959967389     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/138161211796196936     Document Type: Review

References (114)

1. Fan ST, Lai EC, Mok FP, Lo CM, Zheng SS, Wong J. Early treatment of acute biliary pancreatitis by endoscopic papillotomy. N Engl J Med 1993; 328: 228-32.
2. Van Geenen EJ, Mulder CJ, Van der Peet DL, Fockens P, Bruno MJ. Endoscopic treatment of acute biliary pancreatitis: a national survey among Dutch gastroenterologists. Scand J Gastroenterol 2010; 45: 1116-20.
3. Frey CF, Zhou H, Harvey DJ, White RH. The incidence and casefatality rates of acute biliary, alcoholic, and idiopathic pancreatitis in California, 1994-2001. Pancreas 2006; 33: 336-44.
4. Yadav D, Lowenfels AB. Trends in the epidemiology of the first attack of acute pancreatitis: a systematic review. Pancreas 2006; 33: 323-30.
5. Gao YJ, Li YQ, Wang Q, et al. Analysis of clinical features of acute pancreatitis in Shandong Province, China. J Gastroenterol Hepatol 2007; 22: 340-4.
6. Brazeau P, Vale W, Burgus R, et al. Hypothalamic polypeptide that inhibits the secretion of immunoreactive pituitary growth hormone. Science 1973; 179: 77-9.
7. McKay CJ, Imrie CW, Baxter JN. Somatostatin and somatostatin analogues - are they indicated in the management of acute pancreatitis? Gut 1993; 34: 1622-6.
8. Limberg B, Kommerell B. Treatment of acute pancreatitis with somatostatin. N Engl J Med 1980; 303: 284.
9. Choi TK, Mok F, Zhan WH, Fan ST, Lai EC, Wong J. Somatostatin in the treatment of acute pancreatitis: a prospective randomized controlled trial. Gut 1989; 30: 223-7.
10. Usadel KH, Uberla KK, Leuschner U. Treatment of acute pancreatitis with somatostatin: results of the multicentre double-blind trial (APTS). Dig Dis Sci 1985; 30: A992.
11. D'Amico D, Favia G, Biasiato R, et al. The use of somatostatin in acute pancreatitis: results of a multicentre trial. Hepatogastroenterology 1990; 37: 92-8.
12. Carballo F, Dominguez-Munoz JE, Fernandez-Calvet L, et al. Is somatostatin useful in the treatment of acute pancreatitis? A metaanalysis. Digestion 1991; 49: A12-13.
13. Whitcomb DC. Acute pancreatitis: Molecular biology update. J Gastrointest Surg 2003; 7: 940-2.
14. Sutton R, Criddle D, Raraty MG, Tepikin A, Neoptolemos JP, Petersen OH. Signal transduction, calcium and acute pancreatitis. Pancreatology 2003; 3: 497-505.
15. Weber CK, Adler G. From acinar cell damage to systemic inflammatory response: Current concepts in pancreatitis. Pancreatology 2001; 1: 356-62.
16. Halangk W, Lerch MM. Early events in acute pancreatitis. Gastroenterol Clin North Am 2004; 33: 717-31.
17. Bhatia M, Wong FL, Cao Y, et al. Pathophysiology of acute pancreatitis. Pancreatology 2005; 5: 132-44.
18. Hofbauer B, Saluja AK, Lerch MM, et al. Intra-acinar cell activation of trypsinogen during caerulein-induced pancreatitis in rats. Am J Physiol Gastrointest Liver Physiol 1998; 275: G352-62.
19. Otani T, Matsukura A. Premature trypsinogen activation during cerulein pancreatitis in rats occurs inside pancreatic acinar cells. Pancreas 2000; 20: 421-3.
20. Lüthen R, Owen RL, Sarbia M, Grendell JH, Niederau C. Premature trypsinogen activation during cerulein pancreatitis in rats occurs inside pancreatic acinar cells. Pancreas 1998; 17: 38-43.
21. Bhatia M. Apoptosis versus necrosis in acute pancreatitis. Am J Physiol Gastrointest Liver Physiol 2004; 286: G189-96.
22. Meyerholz DK, Samuel I. Morphological Characterization of Early Ligation induced acute pancreatitis in rats. Am J Surg 2007; 194: 652-8.
23. Chen Y, Chong MM, Darwiche R, Thomas HE, Kay TW. Severe Pancreatitis with Exocrine Destruction and Increased Islet Neogenesis in Mice with Suppressor of Cytokine Signaling-1 Deficiency. American Journal of Pathology 2004; 165: 913-21.
24. Büchler MW, Binder M, Friess H. Role of somatostatin and its analogues in the treatment of acute and chronic pancreatitis. Gut 1994; 35(supplement 3): S15-9.
25. Zyromski N, Murr MM. Evolving concepts in the pathophysiology pathophysiology of acute pancreatitis. Surgery 2003; 133: 235-7.
26. Norman JG. New approaches to acute pancreatitis: Role of inflammatory mediators. Digestion 1999; 60(suppl 1): 57-60.
27. Dugernier T, Laterre PF, Reynaert M, Deby-Dupont G. Compartmentalization of the protease-antiprotease balance in early severe acute pancreatitis. Pancreas 2005; 31: 168-73.
28. Takeda K, Mikami Y, Fukuyama S, et al. Pancreatic ischemia associated with vasospasm in the early phase of human acute necrotizing pancreatitis. Pancreas 2005; 30: 40-9.
29. Rau B, Schilling MK, Beger HG. Laboratory markers of severe acute pancreatitis. Dig Dis 2004; 22: 247-57.
30. Chen X, Ji B, Han B, Ernst SA, Simeone D, Logsdon CD. NFkappaB activation in pancreas induces pancreatic and systemic inflammatory response. Gastroenterology 2002; 122: 448-57.
31. Dziurkowska-Marek A, Marek TA, Nowak A, Kacperek-Hartleb T, Sierka E, Nowakowska-Dulława E. The dynamics of the oxidantantioxidant balance in the early phase of human acute biliary pancreatitis. Pancreatology 2004; 4: 215-22.
32. Schulz HU, Niederau C, Klonowski-Stumpe H, Halangk W, Luthen R, Lippert H. Oxidative stress in acute pancreatitis. Hepatogastroenterology 1999; 46: 2736-50.
33. Papachristou GI, Sass DA, Avula H, et al. Is the monocyte chemotactic protein-1 -2518 g allele a risk factor for severe acute pancreatitis? Clin Gastroenterol Hepatol 2005; 3: 475-81.
34. Keck T, Friebe V, Warshaw AL, et al. Pancreatic proteases in serum induce leukocyte-endothelial adhesion and pancreatic microcirculatory failure. Pancreatology 2005; 5: 241-50.
35. Rakonczay Z Jr, Hegyi P, Takács T, McCarroll J, Saluja AK. The role of NF-kB activation in the pathogenesis of acute pancreatitis. Gut 2008; 57: 259-67.
36. Gloor B, Blinman TA, Rigberg DA, et al. Kupffer cell blockade reduces hepatic and systemic cytokine levels and lung injury in hemorrhagic pancreatitis in rats. Pancreas 2000; 21: 414-20.
37. Gloor B, Todd KE, Lane JS, Rigberg DA, Reber HA. Mechanism of increased lung injury after acute pancreatitis in IL-10 knockout mice. J Surg Res 1998; 80: 110-4.
38. Chen CC, Wang SS, Lee FY, et al. Prophylactic octreotide reduces the severity of histopathologic changes and hemodynamic shock in early taurodeoxycholate-induced experimental pancreatitis. Proc Natl Sci Counc Repub China B 1999; 23: 1-6.
39. Ferrer JV, Ariceta J, Guerrero D, Balen E, Herrera J, Lera JM. Prevention by somatostatin and N-acetylcisteine of multiorgan failure mediated by oxidative stress after intestinal ischemia. Transplant Proc 1999; 31: 2570-1.
40. Rau B, Baumgart K, Krüger CM, Schilling M, Beger HG. CCchemokine activation in acute pancreatitis: enhanced release of monocyte chemoattractant protein-1 in patients with local and systemic complications. Intensive Care Med 2003; 29: 622-9.
41. Tang C, Lan C, Wang C, Liu R. Amelioration of the development of multiple organ dysfunction syndrome by somatostatin via suppression of intestinal mucosal mast cells. Shock 2005; 23: 470-5.
42. Wu H, Liu L, Tan QH, et al. Somatostatin limits intestinal ischemia- reperfusion injury in macaques via suppression of TLR4-NF- kB cytokine pathway. J Gastrointestinal Surg 2009; 13: 983-93.
43. Hiruma K, Koike T, Nakamura H, et al. Somatostatin receptors on human lymphocytes and leukaemia cells. Immunology 1990; 71: 480-5.
44. Renold FK, Dazin P, Goetzl EJ, Payan DG. Interleukin-3 modulation of mouse bone marrow derived mast cell receptors for somatostatin. J Neurosci Res 1987; 18: 195-202.
45. Chowers Y, Cahalon L, Lahav M, et al. Somatostatin through its specific receptor inhibits spontaneous and TNF-alpha- and bacteria- induced IL-8 and IL-1 beta secretion from intestinal epithelial cells. J Immunol 2000; 165: 2955-61.
46. Jenkins SA, Ellenbogen S, Day DW, Roberts N, Baxter JN. Effects of SMS 201-995 on reticuloendothelial system (RES) activity in rats with acute pancreatitis. Gut 1987; 28: A1381-5.
47. Baxter JN, Jenkins SA, Day DW, Shields R. The effects of somatostatin analogue (sms 201-995) on hepatic and splenic reticuloendothelial function in rat. Br J Surg 1985; 72: 1005-8.
48. Halangk W, Lerch MM, Brandt-Nedelev B, et al. Role of cathepsin B in intracellular trypsinogen activation and the onset of acute pancreatitis. J Clin Invest 2000; 106: 773-81.
49. Velõsy B, Madácsy L, Szepes A, Pávics L, Csernay L, Lonovics J. The effects of somatostatin and octreotide on the human sphincter of Oddi. Eur J Gastroenterol Hepatol 1999; 11: 897-901.
50. Ahrendt SA, Ahrendt GM, Lillemoe KD, Pitt HA. Effect of octreotide on sphincter of Oddi and gallbladder motility in prairie dogs. Am J Physiol 1992; 262: G909-14.
51. Chen P, Hu B, Tan Q, et al. Role of neurocrine somatostatin on sphincter of Oddi contractility and intestinal ischemia reperfusioninduced acute pancreatitis in macaques. Neurogastroenterology and motility 2010; 22: 935-42.
52. Wu H, Deng YY, Kang Y, Huang MH, Tang CW. Clinical implication of blood somatostatin determination in critically ill patients. Chinese Critical Care Medicine 2009; 21: 307-10.
53. Zhou C, Li J, Wang H, Tang C. Decreased somatostatin is related to the hypersensitivity of intestinal epithelia to LPS via upregulated TLR4-TBK1 pathway in rats chronically exposed to ethanol. Alcohol 2009; 43: 293-303.
54. Kaplan O, Kaplan D, Casif E, et al. Effects of delayed administration of octreotide in acute experimental pancreatitis. J Surg Res. 1996; 62: 109-17.
55. Steinberg WM, Schlesselman SE. Treatment of acute pancreatitis. Comparison of animal and human studies. Gastroenterology 1987; 93: 1420-7.
56. Greenberg R, Haddad R, Kashtan H, Kaplan O. The effects of somatostatin and octreotide on experimental and human acute pancreatitis. J Lab Clin Med 2000; 135: 112-21.
57. Cavallini G, Frulloni L. Somatostatin and octreotide in acute pancreatitis: the never-ending story. Digest Liver Dis 2001; 33: 192- 201.
58. Uhl W, Büchler MW, Malfertheiner P, Beger HG, Adler G, Gaus W. A randomised, double blind, multicentre trial of octreotide in moderate to severe acute pancreatitis. Gut 1999; 45: 97-104.
59. Isenmann R, Rau B, Beger HG. Early severe acute pancreatitis: characteristics of a new subgroup. Pancreas 2001; 22: 274-8.
60. Buter A, Imrie CW, Carter CR, Evans S, McKay CJ. Dynamic nature of early organ dysfunction determines outcome in acute pancreatitis. Br J Surg 2002; 89: 298-302.
61. Papachristou GI, Papachristou DJ, Avula H, Slivka A, Whitcomb DC. Obesity increases the severity of acute pancreatitis: performance of APACHE-O score and correlation with the inflammatory response. Pancreatology 2006; 6: 279-85.
62. Martínez J, Johnson CD, Sánchez-Payá J, de Madaria E, Robles-Díaz G, Pérez-Mateo M. Obesity is a definitive risk factor of severity and mortality in acute pancreatitis: an updated meta-analysis. Pancreatology 2006; 6: 206-9.
63. De Waele B, Vanmierlo B, Van Nieuwenhove Y, Delvaux G. Impact of body overweight and class I, II and III obesity on the outcome of acute biliary pancreatitis. Pancreas 2006; 32: 343-5.
64. Nordback I, Pessi T, Auvinen O, Autio V. Determination of necrosis in necrotizing pancreatitis. Br J Surg 1985; 72: 225-7.
65. Funnell IC, Bornman PC, Weakley SP, Terblanche J, Marks IN. Obesity: an important prognostic factor in acute pancreatitis. Br J Surg 1993; 80: 484-6.
66. Takahashi K, Mizuarai S, Araki H, et al. Adiposity elevates plasma MCP-1 levels leading to the increased CD11b-positive monocytes in mice. J Biol Chem 2003; 278: 46654-60.
67. Mery CM, Rubio V, Duarte-Rojo A, et al. Android fat distribution as predictor of severity in acute pancreatitis. Pancreatology 2002; 2: 543-9.
68. Suazo-Baráhona J, Carmona-Sánchez R, Robles-Díaz G, et al. Obesity: a risk factor for severe acute biliary and alcoholic pancreatitis. Am J Gastroenterol 1998; 93: 1324-8.
69. Lankisch PG, Schirren CA. Increased body weight as a prognostic parameter for complications in the course of acute pancreatitis. Pancreas 1990; 5: 626-9.
70. Porter KA, Banks PA. Obesity as a predictor of severity in acute pancreatitis. Int J Pancreatol 1991; 10: 247-52.
71. Grauvogel J, Daemmrich TD, Ryschich E, Gebhard MM, Werner J. Chronic alcohol intake increases the severity of pancreatitis induced by acute alcohol administration, hyperlipidemia and pancreatic duct obstruction in rats. Pancreatology 2010; 10: 603-12.
72. Miller PM, Spies C, Neumann T, et al. Alcohol biomarker screening in medical and surgical settings. Alcohol Clin Exp Res 2006; 30: 185-93.
73. Thakur L, Kojicic M, Thakur SJ, et al. Alcohol consumption and development of acute respiratory distress syndrome: a populationbased study. Int J Environ Res Public Health 2009; 6: 2426-35.
74. Esper A, Burnham EL, Moss M. The effect of alcohol abuse on ARDS and multiple organ dysfunction. Minerva. Anestesiol 2006; 72: 375-81.
75. Moss M, Parsons PE, Steinberg KP, et al. Chronic alcohol abuse is associated with an increased incidence of acute respiratory distress syndrome and severity of multiple organs dysfunction in patients with septic shock. Crit Care Med 2003; 31: 869-77.
76. Khoruts A, Stahnke L, McClain C, Logan G, Allen J. Circulating tumor necrosis factor, interleukin-1 and interleukin-6 in chronic alcoholic patients. Hepatology 1991; 13: 267-76.
77. Fukui H, Brauner B, Bode JC, Bode C. Plasma endotoxin concentrations in patients with alcoholic and non-alcoholic liver disease: reevaluation with an improved chromogenic assay. J Hepatol 1991; 12: 162-9.
78. Brown LAS, Harris FL, Guidot DM. Chronic ethanol ingestion potentiates TNF-α-mediated oxidative stress and apoptosis in rat type II cells. Am J Physiol Lung Cell Mol Physiol 2001; 281: L377-86.
79. Bai Y, Gao J, Zou DW, Li ZS. Prophylactic octreotide administration does not prevent post-endoscopic retrograde cholangiopancreatography pancreatitis: a meta-analysis of randomized controlled trials. Pancreas 2008; 37: 241-6.
80. Andriulli A, Caruso N, Quitadamo M, et al. Antisecretory vs. Antiproteasic Drugs in the Prevention of Post-ERCP Pancreatitis: The Evidence-Based Medicine Derived from a Meta-Analysis Study. J Pancreas (Online) 2003; 4: 41-8.
81. Raptis S, Schlegel W, Lehman E, Dollinger HC, Zoupas C. Effects of somatostatin on the expcrine pancreas and the release of duodenal hormones. Metabolism 1978; 23: 1321-8.
82. Gjørup I, Roikjaer O, Anderson B, et al. A double-blinded multicenter trial of somatostatin in the treatment of acute pancreatitis. Surg Gynecol Obstet 1992; 175: 397-400.
83. Luengo L, Vicente V, Gris F, et al. Influence of somatostatin in the evolution of acute pancreatitis. A prospective randomized study. Int J Pancreatol 1994; 15: 139-44.
84. Sánchez Rodríguez A, Sánchez Fuentes D, Chimpén Ruiz V, et al. Acute pancreatitis: clinical and therapeutic study with somatostatin. Rev Clin Esp 1997; 197: 96-9.
85. Planas M, PeÂrez A, Iglesia R, Porta I, Masclans JR, Bermejo B. Severe acute pancreatitis: treatment with somatostatin. Intensive Care Med 1998; 24: 37-9.
86. O'Hair DP, Hoffman RG, Schroeder H, Wilson SD. Octreotide in the treatment of acute pancreatitis: a prospective, randomized trial. Gastroenterology 1993; 104(Suppll 4/P.2): A326.
87. Beechey-Newman N. Controlled trial of high-dose octreotide in treatment of acute pancreatitis. Evidence of improvement in disease severity. Dig Dis Sci 1993; 38: 644-7.
88. Binder M, Uhl W, Friess H, Malfertheiner P, Büchler MW. Octreotide in the treatment of acute pancreatitis: results of a unicenter prospective trial with three different octreotide dosages. Digestion 1994; 55(Suppl 1): 20-3.
89. Paran H, Neufeld D, Mayo A, et al. Preliminary report of a prospective randomized study of octreotide in the treatment of severe acute pancreatitis. J Am Coll Surg 1995; 181: 121-4.
90. Fiedler F, Jauernig G, Keim V, Richter A, Bender HJ. Octreotide treatment in patients with necrotizing pancreatitis and pulmonary failure. Intensive Care Med 1996; 22: 909-15.
91. Mckay C, Baxter J, Imrie C. A randomized, controlled trial of octreotide in the management of patients with acute pancreatitis. Int J Pancreatol 1997; 21: 13-9.
92. Uhl W, Malfertheiner P, Adler G, et al. The role of octreotide in human acute pancreatitis. A multicenter study. Digestion 1997; 58(Suppl 2): A32.
93. Karakoyunlar O, Sivrel E, Tanir N, Denecli AG. High dose octreotide in the management of acute pancreatitis. Hepatogastroenterology 1999; 46: 1968-72.
94. Paran H, Mayo A, Paran D, et al. Octreotide treatment in patients with severe acute pancreatitis. Dig Dis Sci 2000; 45: 2247-51.
95. Nikou GC, Arnaoutis TP, Giamarellos-Bourboulis EJ, et al. The significance of the dosage adjustment of octreotide in the treatment of acute pancreatitis of moderate severity. Hepato-gastroenterology 2001; 48: 1754-7.
96. Nikou GC, Giamarellos-Bourboulis EJ, Grecka P, Toumpanakis Ch, Giannikopoulos G, Katsilambros N. Effect of octreotide administration on serum interleukin-6 (IL-6) levels of patients with acute edematous pancreatitis. Hepato-gastroenterology 2004; 51: 599-602.
97. Dollinger HC, Raptis S, Pfeiffer EF. Effects of somatostatin on exocrine and endocrine pancreatic function stimulated by intestinal hormones in man. Horm Metab Res 1976; 8: 74-8.
98. Creutzfeldt W, Lembcke B, Fölsch UR, Schleser S, Koop I. Effect of somatostatin analogue (SMS 201-995, Sandostatin) on pancreatic secretion in humans. Am J Med 1987; 82: 49-54.
99. Lenz T, Kölbel C, Herzog P, Holtermüller KH. Effect of somatostatin on hypercalcemia stimulated gastric juice and exocrine pancreas secretion in the human. Z Gastroenterol 1986; 24: 74-9.
100. Kemmer TP, Malfertheiner P, Büchler M, Friess H, Meschenmoser L, Ditschuneit H. Inhibition of human exocrine pancreatic secretion by the long-acting somatostatin analogue octreotide (SMS 201- 995). Aliment Pharmacol Ther 1992; 6: 41-50.
101. Von der Ohe M, Leben J, Cherian L, Layer P. The synthetic somatostatin analog octreotide: effect on interdigestive pancreas secretion and gastrointestinal motility in man. Med Klin (Munich) 1993; 88 Suppl 1: 18-22.
102. Vatn MH, Schrumpf E, Hanssen KF, Myren J. A small dose of somatostatin inhibits the secretin stimulated secretion of bicarbonate, amylase, and chymotrypsin in man. J Endocrinol Invest 1980; 3: 279-82.
103. Conway DR, Djuricin G, Prinz RA. The effect of somatostatin analogue (SMS 201-995) on pancreatic blood flow. Surgery 1988; 104: 1024-30.
104. Klar E, Rattner DW, Compton C, Stanford G, Chernow B, Warshow AL. Adverse effect of therapeutic vasoconstrictors in experimental acute pancreatitis. Ann Surg 1991; 214: 168-74.
105. Schröder T, Millard RW, Nakajima Y, Gabel M, Joffe SN. Microcirculatory effects of somatostatin in acute pancreatitis. Eur Surg Res 1988; 20: 82-8.
106. Phillips AR, Farrant GJ, Abu-Zidan FM, Cooper GJ, Windsor JA. A method using laser Doppler flowmetry to study intestinal and pancreatic perfusion during an acute intestinal ischaemic injury in rats with pancreatitis. Eur Surg Res 2001; 33: 361-9.
107. Farrant GJ, Abu-Zidan FM, Liu X, Delahunt B, Zwi LJ, Windsor JA. The impact of intestinal ischaemia-reperfusion on caeruleininduced oedematous experimental pancreatitis. Eur Surg Res 2003; 35: 395-400.
108. Plusczyk T, Rathgeb D, Westermann S, Feifel G. Somatostatin Attenuates Microcirculatory Impairment in Acute Sodium Taurocholate-Induced Pancreatitis. Dig Dis Sci 1998; 43: 575-585.
109. Woeste G, Wullstein C, Meyer S, Usadel KH, et al. Octreotide attenuates impaired microcirculation in postischemic pancreatitis when administered before induction of ischemia. Transplantation 2008; 15; 86: 961-7.
110. Del Pozo E, Neufeld M, Schlüter K, et al. Endocrine profile of a long acting somatostatin derivative, SMS 201-995. Study in normal volunteers following subcutaneous administration. Acta Endocrinol 1986; 111: 433-9.
111. Triester SL, Kowdley KV. Prognostic factors in acute pancreatitis. J Clin Gastroenterol. 2002; 34: 167-176.
112. Larvin M, McMahon MJ. APACHE-II score for assessment and monitoring of acute pancreatitis. Lancet 1989; 2: 201-5.
113. Ranson JH, Rifkind KM, Roses DF, et al. Prognostic signs and the role of operative management in acute pancreatitis. Surg Gynecol Obstet 1974; 139: 69-81.
114. Blamey SL, Imrie CW, O'Neill J, Gilmour WH, Carter DC. Prognostic factors in acute pancreatitis. Gut 1984; 25: 1340-6.